Got TEA? Pesticide-Filled Goodness

Glaucus Research, a research-driven short selling firm similar to Muddy Waters/Citron Research, released a report and follow up on this month about the recent deal by Starbucks (NYSE: SBUX) to acquire Teavana Holdings, Inc. (NYSE:TEA). The latter is a retail-based seller of organic/premium tea and is a growing segment for SBUX.

In short, Glaucus alleges that TEA's tea, far from organic and premium, is pesticide-ridden and in violation of EU pesticide standards and by extension US FDA regulations. As a result, SBUX's acquisition (and TEA's entire business) is in danger of falling apart.

What is truly interesting about this particular situation are the odds involved. SBUX's acquisition price of ~$650mm equates to roughly 16$ per share. At current prices of $14.50, conservatively speaking, short sellers are risking $1 per share.



How about the upside? Prior to the sale, TEA was already at 52-week lows at 10.50$ , that's $4 a share downside even if just acquisition fails. However, the reason for such a failure would be a drastic negative on the stock, especially given the due diligence that SBUX would have uncovered to scuttle the deal. In reality, the lower bound of the stock may be $5 or even lower, given legal/business model risk.

So, before further analysis, short sellers are getting better than 2 to 1 odds with a predefined catalyst (acquisition due-diligence)

*Disclosure: I am short TEA

-Stanley

2 Comments
 

Velit eum hic amet ad aliquam corrupti. Consequuntur asperiores at ea expedita suscipit laudantium nobis. Harum reprehenderit et suscipit et. Nisi dolor distinctio suscipit distinctio. Dolores reiciendis natus iure saepe cupiditate. Rerum provident recusandae quaerat est sit ullam. Assumenda quas illum est voluptate.

Laborum et et laudantium sit odit sed quod. Consequatur pariatur explicabo ipsam possimus consequatur molestiae a. Et provident et odit ut expedita quis. Tenetur ex occaecati magni iure commodi hic.

Voluptate ad quia aspernatur ad. Sunt et labore ullam sunt nostrum optio est ratione. Minima veniam asperiores aspernatur sapiente. Non unde magni et ex autem voluptas. Aut aut ea sunt sed.

Career Advancement Opportunities

November 2026 Investment Banking

  • Evercore 01 99.5%
  • Moelis & Company 01 99.0%
  • JPMorgan 01 98.4%
  • Guggenheim Partners 02 97.9%
  • Morgan Stanley 06 97.4%

Overall Employee Satisfaction

November 2026 Investment Banking

  • Moelis & Company No 99.5%
  • Morgan Stanley 02 99.0%
  • Evercore 01 98.4%
  • Banco Santander 04 97.9%
  • BMO Capital Markets 13 97.4%

Professional Growth Opportunities

November 2026 Investment Banking

  • Evercore 01 99.5%
  • Moelis & Company 01 99.0%
  • Morgan Stanley 05 98.4%
  • Goldman Sachs 01 97.9%
  • JPMorgan No 97.4%

Total Avg Compensation

November 2026 Investment Banking

  • Vice President (17) $409
  • Associates (58) $261
  • 3rd+ Year Analyst (8) $210
  • 2nd Year Analyst (29) $183
  • Intern/Summer Associate (16) $161
  • 1st Year Analyst (84) $151
  • Intern/Summer Analyst (77) $101
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

1
redever's picture
redever
99.2
2
Secyh62's picture
Secyh62
99.0
3
BankonBanking's picture
BankonBanking
99.0
4
kanon's picture
kanon
99.0
5
dosk17's picture
dosk17
98.9
6
DrApeman's picture
DrApeman
98.9
7
GameTheory's picture
GameTheory
98.9
8
Betsy Massar's picture
Betsy Massar
98.9
9
CompBanker's picture
CompBanker
98.9
10
Linda Abraham's picture
Linda Abraham
98.8
success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”